The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
RCMP stress importance of having a plan to get home safely during the holidays
Time to start sorting the garbage from Christmas
Kruger VP Talks about a $700M retrofit at Corner Brook Pulp and Paper
RNC to increase patrols during the holidays with a focus on impaired driving
Jim Fidler is out with a Christmas song he wrote 15 years ago
